KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
FRA:PHI1 - NL0000009538 - Common Stock
23.52 EUR
-0.05 (-0.21%)
Taking everything into account, PHI1 scores 3 out of 10 in our fundamental rating. PHI1 was compared to 57 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHI1 had positive earnings in the past year.
PHI1 had a positive operating cash flow in the past year.
In multiple years PHI1 reported negative net income over the last 5 years.
Of the past 5 years PHI1 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.61%, PHI1 is in line with its industry, outperforming 42.11% of the companies in the same industry.
PHI1's Return On Equity of 1.56% is in line compared to the rest of the industry. PHI1 outperforms 42.11% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.00%, PHI1 is in line with its industry, outperforming 42.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROIC | 4% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHI1 has a Profit Margin (0.91%) which is comparable to the rest of the industry.
PHI1 has a Operating Margin (6.11%) which is comparable to the rest of the industry.
PHI1's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 43.85%, PHI1 is doing worse than 68.42% of the companies in the same industry.
PHI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% |
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
Compared to 1 year ago, PHI1 has less shares outstanding
PHI1 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHI1 is higher compared to a year ago.
2.2 Solvency
PHI1 has an Altman-Z score of 1.91. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of PHI1 (1.91) is comparable to the rest of the industry.
PHI1 has a debt to FCF ratio of 19.41. This is a negative value and a sign of low solvency as PHI1 would need 19.41 years to pay back of all of its debts.
The Debt to FCF ratio of PHI1 (19.41) is comparable to the rest of the industry.
PHI1 has a Debt/Equity ratio of 0.69. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
PHI1 has a worse Debt to Equity ratio (0.69) than 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 1.91 |
ROIC/WACC0.64
WACC6.3%
2.3 Liquidity
A Current Ratio of 1.26 indicates that PHI1 should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.26, PHI1 is doing worse than 71.93% of the companies in the same industry.
PHI1 has a Quick Ratio of 1.26. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
PHI1's Quick ratio of 0.81 is on the low side compared to the rest of the industry. PHI1 is outperformed by 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 |
3. Growth
3.1 Past
PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.17%, which is quite good.
The Earnings Per Share has been decreasing by -7.17% on average over the past years.
Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.53% in the last year.
Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 1.00% on average per year.
EPS 1Y (TTM)11.17%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%21.91%
Revenue 1Y (TTM)-1.53%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-2.12%
3.2 Future
Based on estimates for the next years, PHI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.33% on average per year.
PHI1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.97% yearly.
EPS Next Y1.18%
EPS Next 2Y6.04%
EPS Next 3Y8.31%
EPS Next 5Y12.33%
Revenue Next Year-1.51%
Revenue Next 2Y0.97%
Revenue Next 3Y2.19%
Revenue Next 5Y2.97%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.33, PHI1 is valued correctly.
91.23% of the companies in the same industry are more expensive than PHI1, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.08, PHI1 is valued a bit cheaper.
A Price/Forward Earnings ratio of 15.10 indicates a correct valuation of PHI1.
85.96% of the companies in the same industry are more expensive than PHI1, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PHI1 to the average of the S&P500 Index (22.72), we can say PHI1 is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.33 | ||
| Fwd PE | 15.1 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHI1 is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
PHI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.18 | ||
| EV/EBITDA | 12.28 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHI1 does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)13.8
PEG (5Y)N/A
EPS Next 2Y6.04%
EPS Next 3Y8.31%
5. Dividend
5.1 Amount
No dividends for PHI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:PHI1 (8/29/2025, 7:00:00 PM)
23.52
-0.05 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners42.8%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap22.65B
Analysts75.38
Price Target27.4 (16.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.62%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.64%
Min EPS beat(2)22.24%
Max EPS beat(2)31.04%
EPS beat(4)2
Avg EPS beat(4)6.19%
Min EPS beat(4)-16.56%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-1.09%
EPS beat(12)5
Avg EPS beat(12)15.29%
EPS beat(16)5
Avg EPS beat(16)3.51%
Revenue beat(2)0
Avg Revenue beat(2)-1.96%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.22%
Revenue beat(12)2
Avg Revenue beat(12)-1.61%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)6.19%
PT rev (3m)-3.95%
EPS NQ rev (1m)-4.25%
EPS NQ rev (3m)-14%
EPS NY rev (1m)-7.96%
EPS NY rev (3m)-7.96%
Revenue NQ rev (1m)-2.15%
Revenue NQ rev (3m)-6.03%
Revenue NY rev (1m)-2.62%
Revenue NY rev (3m)-2.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.33 | ||
| Fwd PE | 15.1 | ||
| P/S | 1.27 | ||
| P/FCF | 52.18 | ||
| P/OCF | 20.61 | ||
| P/B | 2.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.28 |
EPS(TTM)1.44
EY6.12%
EPS(NY)1.56
Fwd EY6.62%
FCF(TTM)0.45
FCFY1.92%
OCF(TTM)1.14
OCFY4.85%
SpS18.54
BVpS10.78
TBVpS-1.76
PEG (NY)13.8
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROCE | 5.69% | ||
| ROIC | 4% | ||
| ROICexc | 4.43% | ||
| ROICexgc | 14.55% | ||
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% | ||
| FCFM | 2.43% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y10.6%
ROICexcg growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-Score8
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 3.01 | ||
| Cap/Depr | 51.35% | ||
| Cap/Sales | 3.72% | ||
| Interest Coverage | 4 | ||
| Cash Conversion | 46.06% | ||
| Profit Quality | 267.9% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 | ||
| Altman-Z | 1.91 |
F-Score8
WACC6.3%
ROIC/WACC0.64
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.17%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%21.91%
EPS Next Y1.18%
EPS Next 2Y6.04%
EPS Next 3Y8.31%
EPS Next 5Y12.33%
Revenue 1Y (TTM)-1.53%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-2.12%
Revenue Next Year-1.51%
Revenue Next 2Y0.97%
Revenue Next 3Y2.19%
Revenue Next 5Y2.97%
EBIT growth 1Y476.21%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year50.08%
EBIT Next 3Y20.59%
EBIT Next 5YN/A
FCF growth 1Y3516.67%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y43.47%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%